-
ALSO READ
Cold supply chain challenge a big hurdle for equitable Covid-19 vaccination
Pfizer, Serum or Bharat Biotech - whose Covid vaccine will be India's 1st?
First Covishield consignment leaves Serum Institute for 13 locations
Covaxin: Science, not pride will help India build trust in this vaccine
India to gift 2 mn doses of Covid-19 vaccine 'Covishield' to Bangladesh
-
The Drug Regulatory Authority of Pakistan (DRAP) has approved a Covid-19 vaccine by China's Sinopharm for emergency use amid an unabated resurgence in the country.
A handout by DRAP on its official website late Monday said that Sinopharm, one of the two vaccines approved by the authority, has been given emergency use authorization after evaluating its safety and quality, Xinhua news agency reported.
The handout added that the authorization will be reviewed every quarter keeping in view further data regarding safety, efficacy and quality.
Meanwhile, another vaccine manufactured by British-Swedish pharmaceutical company AstraZeneca was been given the authorization earlier, the handout said.
Chaudhry Fawad Hussain, the country's Minister for Science and Technology, told Xinhua earlier that the Sinopharm vaccine has been approved for procurement by a cabinet committee for its safety and affordability.
Pakistan reported 1,920 new coronavirus infections and 46 deaths in the last 24 hours, bringing the total number of cases to 521,211 with 10,997 fatalities.
--IANS
ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU